Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL

We previously reported that the NO-modified form of HIV protease inhibitor Saquinavir (Saq) is a potent antitumoral agent efficient against numerous tumor cell lines in vitro and in vivo. In acute toxicity studies, doses of Saq-NO equivalent to DL100 of the parental drug were completely nontoxic. Beside direct effect on malignant cell growth, Saq-NO sensitizes certain type of cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death. In this study, we evaluated the effects of Saq-NO on androgen-dependent prostate cancer LNCaP. Saq-NO inhibited both the growth of LNCaP cells in vitro and in xenograft models. Suppression of tumor growth was accompanied with cell cycle arrest in G0/G1 phase and established a persistent inhibition of proliferation. Furthermore, Saq-NO reverted sensitivity of LNCaP cells to TRAIL but not to TNF. Treatment of cells with Saq-NO induced transient upregulation of Akt and ERK1/2. This, however, did not represent the primary mode of action of Saq-NO, as elimination with specific inhibitors did not compromise the chemotherapic efficacy of the drug. However, permanent abrogation of phosphorylation of the S6 protein, which is the downstream target of both signaling pathways, was observed. Diminished S6 phosphorylation was associated with re-established sensitivity to TRAIL and reduction of X-linked inhibitor of apoptosis protein (XIAP). In summary, NO modification of Saq led to a new chemical entity with stronger and more pleiotropic antitumor activity than the parental drug.

[1]  A. Kim,et al.  The expanding relevance of nuclear mTOR in carcinogenesis , 2011, Cell cycle.

[2]  M. Smyth,et al.  Targeting death-inducing receptors in cancer therapy , 2007, Oncogene.

[3]  M. Donia,et al.  In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells , 2011, Cell cycle.

[4]  E. Rosen,et al.  Pretreatment of indole‐3‐carbinol augments TRAIL‐induced apoptosis in a prostate cancer cell line, LNCaP , 2003, FEBS letters.

[5]  S. Brand,et al.  The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. , 2011, Endocrine-related cancer.

[6]  G. Thomas,et al.  The modular phosphorylation and activation of p70s6k , 1997, FEBS letters.

[7]  T. Wilson,et al.  Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells , 2008, Molecular Cancer Therapeutics.

[8]  Massimo Libra,et al.  Targeting prostate cancer based on signal transduction and cell cycle pathways , 2008, Cell cycle.

[9]  Gen Sheng Wu.  TRAIL as a target in anti-cancer therapy. , 2009, Cancer letters.

[10]  Min Guan,et al.  Anti-HIV drugs for cancer therapeutics: back to the future? , 2009, The Lancet. Oncology.

[11]  M. Berger,et al.  mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells , 2005, Molecular and Cellular Biology.

[12]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Ronald W. Lewis,et al.  SAHA‐sensitized prostate cancer cells to TNFα‐related apoptosis‐inducing ligand (TRAIL): Mechanisms leading to synergistic apoptosis , 2006, International journal of cancer.

[14]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[15]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[16]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging , 2011, Aging.

[17]  J. Tschopp,et al.  FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. , 1998, Journal of immunology.

[18]  V. Rodrik-Outmezguine,et al.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1 , 2011, Cell cycle.

[19]  J. Moffat,et al.  Inhibition of SREBP1 sensitizes cells to death ligands , 2011, Oncotarget.

[20]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[21]  O. Meyuhas,et al.  Vertebrate mRNAs with a 5'-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element , 1994, Molecular and cellular biology.

[22]  W. El-Deiry,et al.  TRAIL death receptors as tumor suppressors and drug targets , 2008, Cell cycle.

[23]  Junho Chung,et al.  Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells , 2010, Apoptosis.

[24]  R. Korneluk,et al.  Functional Characterization of the X-Linked Inhibitor of Apoptosis (XIAP) Internal Ribosome Entry Site Element: Role of La Autoantigen in XIAP Translation , 2000, Molecular and Cellular Biology.

[25]  S. Wheatley,et al.  Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro , 2011, Cell cycle.

[26]  M. Donia,et al.  Cytotoxic and immune‐sensitizing properties of nitric oxide‐modified saquinavir in iNOS‐positive human melanoma cells , 2011, Journal of cellular physiology.

[27]  K. Nastiuk,et al.  FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells , 2008, Oncogene.

[28]  P. Monini,et al.  Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. , 2003, The Lancet. Oncology.

[29]  I. Sancho-Martinez,et al.  Tyrosine phosphorylation and CD95: A FAScinating switch , 2009, Cell cycle.

[30]  D. Seol,et al.  Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein. , 2005, Experimental oncology.

[31]  G. Miller,et al.  Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis* , 2001, The Journal of Biological Chemistry.

[32]  Stephen L. Abrams,et al.  Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy , 2011, Oncotarget.

[33]  Matthias Mann,et al.  FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC) , 1997, The EMBO journal.

[34]  R. Pearson,et al.  Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k , 1997, The EMBO journal.

[35]  E. Grimm,et al.  Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines* , 2004, Journal of Biological Chemistry.

[36]  R. Pieper,et al.  Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme , 2006, Expert review of anticancer therapy.

[37]  Ingo Schmitz,et al.  The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[38]  F. Nicoletti,et al.  The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. , 2011, Antiviral research.

[39]  J. McCubrey,et al.  The antitumor properties of a nontoxic, nitric oxide–modified version of saquinavir are independent of Akt , 2009, Molecular Cancer Therapeutics.

[40]  P. Scheurich,et al.  Inhibition of Death Receptor-mediated Gene Induction by a Cycloheximide-sensitive Factor Occurs at the Level of or Upstream of Fas-associated Death Domain Protein (FADD)* , 2000, The Journal of Biological Chemistry.

[41]  H. Ford,et al.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[42]  J. Kahn,et al.  HIV-1 protease inhibitors. A review for clinicians. , 1997 .